Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to ... yet another potential use for the versatile drug class. The small, 48-subject study – published in the journal JAMA ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

The toxic bite of a Gila monster can kill a human, but a specific ingredient in the cocktail of the lizard's venom is the reason we have glucagon-like peptide (GLP-1) agonists like Ozempic and Wegovy.

“I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards important clinical readouts later this year,” said Mr. Azelby. “I look forward to working with Terns’ ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. GLP-1 agonist drugs like Ozempic and Wegovy have surged in popularity during the last ...

While he points out that the trial was small, he also calls the findings “highly encouraging." GLP-1 receptor agonists are already being used to treat alcohol use disorder in some circumstances ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

While he points out that the trial was small, he also calls the findings “highly encouraging." GLP-1 receptor agonists are ...

Palatin Technologies, Inc. (AMEX: PTN) Q2 2025 Earnings Call Transcript February 13, 2025 ...